BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on filgrastim, pegfilgrastim, lipegfilgrastim and lenograstim: new warnings regarding aortitis associated with the use of granulocyte colony-stimulating factors (G-CSF)

Active substance: filgrastim, pegfilgrastim, lipegfilgrastim, lenograstim

In agreement with the Federal Institute for Drugs and Medical Devices (BFARM), the marketing authorisation holders are circulating information on the risk of aortitis associated with the administration of granulocyte colony-stimulating factors (G-CSF).

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 444KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK